(AGENPARL) - Roma, 4 Marzo 2025 - (AGENPARL) – mar 04 marzo 2025 Lund, Sweden, 4 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA)
today announced it will attend Leerink Partners Global Healthcare Conference on
10-12 March in Miami, FL. Hansa management will be available for meetings at the
conference. If you are interested in meeting with the management team, please
To learn more about Hansa Biopharma see the latest Corporate
Presentation here. (https://www.hansabiopharma.com/investors/presentations
-events/) The latest investor presentation can be
viewed here (https://www.hansabiopharma.com/investors/financial-reports/).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3MpvDacW8Vp1MF9hbRE6osCeTeycwAK8FXsGLUerEuyfh4NujxznpbAgqWUvAND6CcD3HR3Qxa5v3GkTfjT5EBg2JTEeCpiz2vnKpqfMXpdSoS.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3MpvDacW8Vp1MF9hbRE6osCeTeycwAK8FXsGLUerEuyfh4NujxznpbAgqWUvAND6CcD3HR3Qxa5v3GkTfjT5EBg2JTEeCpiz2vnKpqfMXpdSoS.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Antisemitismo, Giglio Vigna (Lega): Legge di civiltà, la sinistra attacchi Hamas con lo stesso vigore
- UGEI: “DDL ANTISEMITISMO APPROVATO, L’ITALIA SCEGLIE DI NON VOLTARSI DALL’ALTRA PARTE”
- SAN SIRO, SISLER (FDI): «SALA DÀ LEZIONI DI URBANISTICA? PENSI AL DISASTRO CHE HA CREATO A MILANO»
- IL COMUNE COMUNICA – Parco della Rinascita: oggi pomeriggio il sopralluogo del sindaco Leccese
- ANTONIO DI PIETRO A FILOROSSO (RAI 3): “SAREBBE BELLO AVERE UN CSM DOVE NON CI SONO SOLO LE CORRENTI”
- DDL ANTISEMITISMO, SAVINO (MEF): “SEGNALE POLITICO CHIARO, NESSUNO SPAZIO PER ODIO E DISCRIMINAZIONI”
- Indiscrezione: Mostra su Pino Rauti alla Camera, chiesta la rimozione di simboli e immagini riconducibili al fascismo: polemiche a Montecitorio
- AGENDA CAMERA DI DOMANI, MERCOLEDÌ 18 NOVEMBRE
- L’Ambasciata d’Italia a Washington celebra la Settimana della Cucina Italiana nel Mondo con due iniziative dedicate alla promozione del patrimonio agroalimentare italiano
- DAERA News Release – MUIR ANNOUNCES PREVENTION ZONE AND HOUSING ORDER AS CO TYRONE BIRD FLU CASE CONFIRMED